Blumea balsamifera Extract Induces Apoptosis and Inhibit Cell Migration on HepG2 Hepatocellular Carcinoma: An Integrated Experimental and Computational Study
DOI:
https://doi.org/10.48048/tis.2026.12369Keywords:
Apoptosis, Blumea balsamifera, Cell migration, Hepatocellular carcinomaAbstract
Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and requires alternative therapeutic strategies beyond current treatments. Blumea balsamifera is a medicinal plant with potential anticancer properties that may offer a novel approach for HCC treatment. This study aimed to evaluate the anti-HCC activity of B. balsamifera extract through an integrated experimental and computational approach. Experimental assays were performed to assess cytotoxicity, apoptosis induction, mitochondrial membrane potential, and cell migration, while computational analyses were applied to predict the molecular mechanisms involved using network pharmacology, molecular docking, and molecular dynamic simulation. The extract demonstrated cytotoxic activity against HepG2 cells (IC₅₀ = 199.09 ± 11.86 µg/mL) and significantly induced apoptosis in a dose-dependent manner, with the IC₅₀ concentration triggering apoptosis in more than 80% of cells. In addition, B. balsamifera extract markedly inhibited HepG2 cell migration, with 74% of the wound gap remaining open at the IC₅₀ concentration. Network pharmacology analysis further predicted that the bioactive compounds of B. balsamifera may act by targeting key HCC-related proteins involved in cell death and migration pathways, including TOP1, AKT1, PPM1D, SRC, AKR1C2, DNMT1, and PTH. Collectively, these findings provide both experimental evidence and computational insights supporting the potential of B. balsamifera as a promising natural therapeutic candidate for hepatocellular carcinoma.
HIGHLIGHTS
- Blumea balsamifera extract induces apoptosis and inhibits migration in HepG2 cells.
- Network pharmacology identified nine active compounds targeting 190 HCC-related proteins.
- Docking and MD simulations confirmed stable binding to key targets (TOP1, AKT1, PPM1D, SRC, AKR1C2, DNMT1, PTH).
- Findings support balsamifera as a potential multi-target natural therapeutic for HCC.
GRAPHICAL ABSTRACT
Downloads
References
F Bray, M Laversanne, H Sung, J Ferlay, RL Siegel, I Soerjomataram and A Jemal. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024; 74(3), 229-263.
YC Shen, HC Hsu, TM Lin, YS Chang, LF Hu, LF Chen, SH Lin, PI Kuo, WS Chen, YC Lin, JH. Chen, YC Liang and CC Chang. H1-Antihistamines reduce the risk of hepatocellular carcinoma in patients with hepatitis B virus, hepatitis C virus, or dual hepatitis B virus-hepatitis C virus infection. Journal of Clinical Oncology 2022; 40(11), 1206-1219.
J Balogh, D Victor, EH Asham, SG Burroughs, M Boktour, A Saharia, X Li, RM Ghobrial and HP Monsour. Hepatocellular carcinoma: A review. Journal of Hepatocellular Carcinoma 2016; 3, 41-53.
D Papaconstantinou, DI Tsilimigras and TM Pawlik. Recurrent hepatocellular carcinoma: Patterns, detection, staging and treatment. Journal of Hepatocellular Carcinoma 2022; 9, 947-957.
J Zheng, S Wang, L Xia, Z Sun, KM Chan, R Bernards, W Qin, J Chen, Q Xia and H Jin. Hepatocellular carcinoma: Signaling pathways and therapeutic advances. Signal Transduction and Targeted Therapy 2025; 10(1), 35.
Z Kan, H Zheng, X Liu, S Li, TD Barber, Z Gong, H Gao, K Hao, MD Willard, J Xu, R Hauptschein, PA Rejto, J Fernandez, G Wang, Q Zhang, B Wang, R Chen, J Wang, NP Lee, W Zhou, Z Lin, Z Peng, K Yi, S Chen, L Li, X Fan, J Yang, R Ye, J Ju, K Wang, H Estrella, S Deng, P Wei, M Qiu, IH Wulur, J Liu, ME Ehsani, C Zhang, A Loboda, WK Sung, A Aggarwal, RT Poon, ST Fan, J Wang, J Hardwick, C Reinhard, H Dai, Y Li, JM Luk and M Mao. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research 2013; 23(9), 1422-1433.
A Fernandez-Medarde and E Santos. Ras in Cancer and Developmental Diseases. Genes & Cancer 2011; 2(3), 344-358.
AJ Gosalia, P Martin and PD Jones. Advances and future directions in the treatment of hepatocellular carcinoma, Gastroenterology & Hepatology 2017; 13(7), 398-410.
IG Widhiantara and IM Jawi. Phytochemical composition and health properties of Sembung plant (Blumea balsamifera): A review. Veterinary World 2021; 14(5), 1185-1196.
A Schieber, P Keller, P Streker, I.Klaiber and R Carle. Detection of isorhamnetin glycosides in extracts of apples (Malus domestica cv. “Brettacher”) by HPLC‐PDA and HPLC‐APCI‐MS/MS. Phytochemical Analysis 2002; 13(2), 87-94.
W Wang, X Yuan, J Mu, Y Zou, L Xu, J Chen, X Zhu, B Li, Z Zeng, X Wu, Z Yin and Q Wang. Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways. Phytomedicine 2023; 118, 154933.
NLPDPP Sari, NLPEK Sari, PNC Santoso, ES Dewi, DPO Lestari, A Lestarini and NW Armerinayanti. Anticancer Activity Test of 70% Alcohol Extract of Sembung Leaves (Blumea balsamifera) Against Cervical Cancer Cells In-Vitro. BIO Web Conference 2025; 184, 01011.
NA Ismail, A Matawali, PC Lee and J Gansau. Blumea balsamifera (L.) DC. Elicit Anti-Kinase, Anti-Phosphatase and Cytotoxic Activities against Acute Promyelocytic Leukemia Cells (HL-60). Tropical Journal of Natural Product Research 2021; 5(4), 656-660.
Y Pang, D Wang, Z Fan, X Chen, F Yu, X Hu, K Wang and L Yuan. Blumea balsamifera—A Phytochemical and Pharmacological Review. Molecules 2014; 19(7), 9453-9477.
T Norikura, A Kojima-Yuasa, M Shimizu, X Huang, S Xu, S Kametani, SN Rho, DO Kennedy and I Matsui-Yuasa. Mechanism of growth inhibitory effect of Blumea balsamiferaExtract in hepatocellular carcinoma. Bioscience, Biotechnology, and Biochemistry 2008; 72(5), 1183-1189.
MH Widyananda, ST Wicaksono, K Rahmawati, S Puspitarini, SM Ulfa, YD Jatmiko, M Masruri and N Widodo. A Potential Anticancer Mechanism of Finger Root (Boesenbergia rotunda) Extracts against a Breast Cancer Cell Line. Scientifica 2022; 2022, 9130252.
MH Widyananda, L Muflikhah, SM Ulfa and N Widodo. Unveiling the antibreast cancer mechanism of Euphorbia hirta ethanol extract: Computational and experimental study. Journal of Biologically Active Products from Nature 2024; 14(3), 359-382.
N Widodo, S Puspitarini, MH Widyananda, A Alamsyah, ST Wicaksono, M Masruri and YD Jatmiko. Anticancer activity of Caesalpinia sappan by downregulating mitochondrial genes in A549 lung cancer cell line [version 2; peer review: 2 approved]. F1000Research 2022; 11, 169.
FSK amila, Y Annisa, N Rosyadah, FE Hermanto, MH Widyananda, DR Dwijayanti and N Widodo. Evaluation of polyphenol and antioxidant properties of Blumea balsamifera extract as potential therapeutic for breast cancer. BIO Web of Conferences 2025; 154, 03004.
M Kuhn, D Szklarczyk, S Pletscher-Frankild, TH Blicher, C Von Mering, LJ Jensen and P Bork. STITCH 4: Integration of protein–chemical interactions with user data. Nucleic Acids Research 2014; 42(D1), D401-D407.
NM O’Boyle, M Banck, CA James, C Morley, T Vandermeersch and GR Hutchison. Open Babel: An open chemical toolbox. Journal of Cheminformatics 2011; 3(1), 33.
S Dallakyan and AJ Olson. Small-Molecule Library Screening by Docking with PyRx. In: JE. Hempel, CH Williams and CC Hong (Eds.). Chemical biology, Springer, New York, 2015, pp. 243-250.
E Krieger and G Vriend. New ways to boost molecular dynamics simulations. Journal of Computational Chemistry 2015; 36(13), 996-1007.
J Yammine, A Fathima, A Gharsallaoui, MZ Masalmeh, M Hasan, HC Yalcin, L Karam and AA Shaito Nanoencapsulation mitigates the toxicity of thymol in human cells and zebrafish embryos. International Journal of Food Properties 2018; 28(1), 2573183
V Shrihastini, P Muthuramalingam, S Adarshan, M Sujitha, JT Chen and H Shin. M. Ramesh, plant derived bioactive compounds, their anti-cancer effects and In Silico approaches as an alternative target treatment strategy for breast cancer: An updated overview. Cancers 2021; 13(24), 6222.
D Basak, S Arrighi, Y Darwiche and S Deb. Comparison of anticancer drug toxicities: Paradigm shift in adverse effect profile. Life 2021; 12(1), 48.
P Biswas, D Dey, PK Biswas, TI Rahaman, S Saha, A Parvez, DA Khan, NJ Lily, K Saha, M Sohel, MM Hasan, S Al Azad, S Bibi, MDN Hasan, M Rahmatullah, J Chun, MDA Rahman and B Kim. A comprehensive analysis and anti-cancer activities of quercetin in ros-mediated cancer and cancer stem cells. International Journal of Molecular Sciences 2022; 23(19), 11746.
MH Widyananda, SK Pratama, ANM Ansori, Y Antonius, VD Kharisma, AAA Murtadlo, V Jakhmola, M Rebezov, M Khayrullin, M Derkho, E Ullah, RJK Susilo, S Hayaza, AP Nugraha, A Proboningrat, A Fadholly, MT Sibero and R Zainul. Quercetin as an anticancer candidate for glioblastoma multiforme by targeting AKT1, MMP9, ABCB1, and VEGFA: An in silico study. Karbala International Journal of Modern Science 2023; 9(3), 450-459.
E Gottlieb, SM Armour, MH Harris and CB Thompson. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death & Differentiation 2003; 10(6), 709-717.
A Jabłońska-Trypuć, M Matejczyk and S Rosochacki. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. Journal of Enzyme Inhibition and Medicinal Chemistry 2016; 31(1), 177-183.
SW Marseti, FE Hermanto, MH Widyananda, N Rosyadah, FS Kamila, Y Annisa, DR Dwijayanti, SM Ulfa and N Widodo. Pharmacological potential of Clinacanthus nutans: Integrating network pharmacology with experimental studies against lung cancer. Journal of Biologically Active Products from Nature 2024; 14(3), 343-358.
KM Knights, A Rowland and JO Miners. Renal drug metabolism in humans: The potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP ‐glucuronosyltransferase (UGT). British Journal of Clinical Pharmacology 2013; 76(4), 587-602.
S Deng, HC Leong, A Datta, V Gopal, AP Kumar and CT Yap. PI3K/AKT signaling tips the balance of cytoskeletal forces for cancer progression. Cancers 2022; 14(7), 1652.
Y Hayashi, Y Toyomasu, SA Saravanaperumal, MR Bardsley, JA Smestad, A Lorincz, ST Eisenman, G Cipriani, MH Nelson Holte, FJ Al Khazal, SA Syed, GB Gajdos, KM Choi, GJ Stoltz, KE Miller, ML Kendrick, BP Rubin, SJ Gibbons, AE Bharucha, DR Linden, LJ Maher, G Farrugia and T Ordog. Hyperglycemia increases interstitial cells of cajal via MAPK1 and MAPK3 signaling to etv1 and kit, leading to rapid gastric emptying. Gastroenterology 2017; 153(2), 521-535.
F Wang, H Zhang, H Wang, T Qiu, B He and Q Yang. Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations. Medical Oncology 2022; 39(12), 180.
K Sargsyan, C Grauffel and C Lim. How molecular size impacts RMSD applications in molecular dynamics simulations. Journal of Chemical Theory and Computation 2017; 13(4), 1518-1524.
AMD Fonseca, BJ Caluaco, JMC Madureira, SQ Cabongo, EM Gaieta, F Djata, RP Colares, MM Neto, CFC Fernandes, GS Marinho, HSD Santos and ES Marinho. Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking, and approach with molecular dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA. Molecular Biotechnology 2023; 66, 1919-1933.
D Chen, N Oezguen, P Urvil, C Ferguson, SM Dann and TC Savidge. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Science Advances 2016; 2(3), e1501240.
MM Madkour, WS Ramadan, E Saleh and R El-Awady. Epigenetic modulations in cancer: Predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors. Annals of Medicine 2023; 55(1), 2203946.
T Chen, S Mahdadi, M Vidal and S Desbène-Finck. Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy. Pharmacological Research 2024; 207, 107328.
Z Andrysik, KD Sullivan, JS Kieft and JM Espinosa. PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response. Nature Communication 2022, 13(1), 7400.
S Noshita, Y Kubo, K Kajiwara, D Okuzaki, S Nada and M Okada. A TGF-β-responsive enhancer regulates SRC expression and epithelial–mesenchymal transition-associated cell migration. Journal of Cell Science 2023; 136(15), jcs261001.
CFL Gonçalves, F Hecht, J Cazarin, RS Fortunato, M Vaisman, DPD Carvalho and ACF Ferreira. The flavonoid quercetin reduces cell migration and increases NIS and E-cadherin mRNA in the human thyroid cancer cell line BCPAP. Molecular and Cellular Endocrinology 2021; 529, 111266.
XZ Xiao, LY Lin, MK Zhuang, CM Zhong and FL Chen. Roles of AKR1C3 in malignancy. Chinese Medical Journal 2021; 134(9), 1052-1054.
IWY Mak, RW Cowan, RE Turcotte, G Singh and M Ghert. pthrp induces autocrine/paracrine proliferation of bone tumor cells through inhibition of apoptosis. PLoS ONE 2011; 6(5), e19975.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
